Outlook
From the latest edition of each brief.
Biotech & Pharma Intelligence
Our 30, 60 and 90 day view is unchanged from Thursday: rates and a falling market may be the main risk, while drugmakers keep licensing early platforms.
| Horizon | What we expect | What would change it | Odds |
|---|---|---|---|
| 30 days | Goal dates on 11.22, 11.27 and 11.30, the CMS negotiated prices due by 11.30 and the 12.09 FOMC, where a hike is priced in futures, as reported, set the news flow | A hold or a 50 basis point move at the 12.09 FOMC | · |
| 60 days | SUO (12.02), ASH (12.12 to 12.15) and year-end goal dates lead the calendar | A biopharma acquisition of $5B or more (call 9 in 15) | · |
| 90 days | RAS drugs in pancreatic cancer may draw more first-line data and trials, with randomized results still ahead | A further rise in the 10-year yield, now 5.04% | · |
Dates from 14 Verified Catalyst Calendar; odds only where a logged call in 15 sets them. Analysis
RED TEAM
Our outlook has not moved while the market fell six days running, as reported. If the sell-off spreads, the risk to small biotech may be larger than our rates line suggests. Analysis
AI & Technology Intelligence
30 days. Monthly options expired Friday. Dell reports 11.24, Marvell 12.01, Salesforce 12.02, and the Fed meets 12.08 to 12.09, with Broadcom reporting 12.09. Huang is reported to have agreed to interviews with House committees on 12.01. Our scenario odds are unchanged. Analysis
60 days. Comments on Commerce’s remote-access rule are due 01.19.2027. The new Congress convenes in January; we found no federal data center moratorium bill. Analysis
90 days. The big cloud buyers report December-quarter results and 2027 spending plans in late January. That is the first hard test of whether this sell-off reflects spending that is slowing. Speculation
RED TEAM
Markets can keep falling or recover long before any of these dates, and spending guidance can change between earnings reports.

